Suggested Readings
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
Bruce IN, et al. Lupus Sci Med. 2023;10(1):e000761.
Safety and efficacy of belimumab in patients with lupus nephritis: open-label extension of BLISS-LN study.
Furie R, et al. Clin J Am Soc Nephrol. 2022;17(11):1620-1630.
A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus.
Kalunian KC, et al. Arthritis Rheumatol. 2023;75(2):253-265.
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
Morand EF, et al. Lancet Rheum. 2022;4(4):e282-e292.
Trial of anifrolumab in active systemic lupus erythematosus.
Morand EF, et al. N Engl J Med. 2020;382(3):211-221.
Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus.
Wallace DJ, et al. Arthritis Rheumatol. 2019;71(7):1125-1134.
Linked Resources
DISEASE MANAGEMENT GUIDELINES
2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus: guideline summary.
European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus: 2023 update.
Fanouriakis A, et al. Ann Rheum Dis. 2024;83(1):15-29.
PATIENT RESOURCES
American College of Rheumatology
Lupus Foundation of America
Lupus Research Alliance
Related activities



Webcast
0.50 CME/CE
An Overview of New ACR Lupus Clinical Practice Guidelines
Module 1
Faculty: | Maria Dall’Era, MD |
Release: | 05/30/2025 |
Expiration: | 05/30/2026 |